Targeting metabolic dysregulation for fibrosis therapy

X Zhao, JYY Kwan, K Yip, PP Liu, FF Liu - Nature reviews Drug …, 2020 - nature.com
Fibrosis is the abnormal deposition of extracellular matrix, which can lead to organ
dysfunction, morbidity, and death. The disease burden caused by fibrosis is substantial, and …

Therapeutic targets in lung tissue remodelling and fibrosis

G Liu, AM Philp, T Corte, MA Travis, H Schilter… - Pharmacology & …, 2021 - Elsevier
Structural changes involving tissue remodelling and fibrosis are major features of many
pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD) and …

Developmental pathways in the pathogenesis of lung fibrosis

D Chanda, E Otoupalova, SR Smith, T Volckaert… - Molecular aspects of …, 2019 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a progressive and terminal lung disease with no known
cure. IPF is a disease of aging, with median age of diagnosis over 65 years. Median survival …

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?

M Sweeney, B Corden, SA Cook - EMBO molecular medicine, 2020 - embopress.org
Cardiac fibrosis is central to the pathology of heart failure, particularly heart failure with
preserved ejection fraction (HF p EF). Irrespective of the underlying profibrotic condition (eg …

Extracellular matrix in lung development, homeostasis and disease

Y Zhou, JC Horowitz, A Naba, N Ambalavanan… - Matrix Biology, 2018 - Elsevier
The lung's unique extracellular matrix (ECM), while providing structural support for cells, is
critical in the regulation of developmental organogenesis, homeostasis and injury-repair …

The myofibroblast, a key cell in normal and pathological tissue repair

IA Darby, N Zakuan, F Billet, A Desmoulière - Cellular and Molecular Life …, 2016 - Springer
Myofibroblasts are characterized by their expression of α-smooth muscle actin, their
enhanced contractility when compared to normal fibroblasts and their increased synthetic …

Is target-based drug discovery efficient? Discovery and “off-target” mechanisms of all drugs

A Sadri - Journal of medicinal chemistry, 2023 - ACS Publications
Target-based drug discovery is the dominant paradigm of drug discovery; however, a
comprehensive evaluation of its real-world efficiency is lacking. Here, a manual systematic …

Autophagy inhibition-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis

C Hill, J Li, D Liu, F Conforti, CJ Brereton, L Yao… - Cell death & …, 2019 - nature.com
Idiopathic pulmonary fibrosis (IPF), the prototypic progressive fibrotic interstitial lung
disease, is thought to be a consequence of repetitive micro-injuries to an ageing …

A novel antifibrotic mechanism of nintedanib and pirfenidone. Inhibition of collagen fibril assembly

L Knüppel, Y Ishikawa, M Aichler… - American journal of …, 2017 - atsjournals.org
Idiopathic pulmonary fibrosis (IPF) is characterized by excessive deposition of extracellular
matrix, in particular, collagens. Two IPF therapeutics, nintedanib and pirfenidone, decelerate …

Fibroblast senescence in idiopathic pulmonary fibrosis

Y Lin, Z Xu - Frontiers in Cell and Developmental Biology, 2020 - frontiersin.org
Aging is an inevitable and complex natural phenomenon due to the increase in age. Cellular
senescence means a non-proliferative but viable cellular physiological state. It is the basis of …